Treatment of equine degenerative joint disease with autologous peripheral blood-derived mesenchymal stem cells: a case report
- J. H. Spaas
- M. Oosterlinck
- S. Broeckx
- M. Dumoulin
- J. Saunders
- A. Van Soom
- F. Pille
- G. R. Van de Walle
Abstract
A 5-year-old German Warmblood stallion with chronic lameness, attributable to degenerative joint disease (DJD) of the pastern joint unresponsive to medical treatments, was treated with autologous mesenchymal stem cells (MSC). These MSC were isolated from the peripheral blood (PB) of the patient and injected into the pastern joint, at a concentration of 2.5x106 cells, twice with an 8-week interval. The positive response to this stem cell treatment was documented by visual gait evaluation as well as objective pressure plate analyses. This paper is the first to describe the use of autologous PB-derived MSC to treat a horse suffering from chronic DJD. The favorable outcome of this single case may stimulate further research on the use of equine peripheral blood as a source of autologous MSC in equine regenerative medicine.
Downloads:
Download PDF
View PDF